$ALC

Alcon said it is expanding toric lens parameter options for Precision1, Precision7 and Total30 at Optometry’s Meeting. The company claims Precision7 and Total30 can support 99% of astigmatic eyes, and Precision1 has at least 28% more parameters than other daily lenses. Alcon says Total30 options are available now, with Precision1 and Precision7 later this year.

Swiss stocks closed higher on Tuesday. The SMI rose 1.04% to 14,571.33, a new 52-week high at 14,583.81. Sika gained 9.8% after reporting H1 2026 net profit of CHF 552.1m (-0.4%) and lowering EPS slightly, while raising full-year sales growth guidance to 3%-6% (local currency). Other gainers included Straumann, Schindler, Geberit, and Nestle; VAT Group fell about 3%.

RBC Capital Markets co-heads of global research Graeme Pearson and Mark Odendahl updated their “Top 30” global stock list, adding Apotex Health, Canadian National Railway, Lonza and deleting Alcon, Boston Scientific and DuPont. The list returned 11.1% in USD in Q2/26. Separate notes cover Scotiabank’s view on KMP REIT rents and BofA’s metals outlook, cutting 32 price objectives and highlighting CCJ, FCX and PAAS.

Alcon Inc. (NYSE:ALC) was discussed as a healthcare stock. TheFly reported July 2 that Argus cut its ALC price target to $85 from $90 while keeping a Buy rating, citing a stronger 2026 earnings outlook (10% to 13% growth) and regulatory submissions expected in 2027 and 2028. On July 6, Alcon and RxSight (RXST) announced a non-exclusive collaboration on adjustable presbyopia-correcting PCIOLs, with RxSight receiving $60 million upfront plus up to $140 million in milestones.

Alcon (ALC) and RxSight (RXST) announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). RxSight will get a $60M upfront payment and up to $140M more tied to development/regulatory milestones. Alcon will lead commercialization; RxSight will handle development/manufacturing and earn royalties. Alcon shares rose to $68.42; RxSight fell.

Alcon (NYSE: ALC) and RxSight (NASDAQ: RXST) announced a non-exclusive collaboration to co-develop adjustable presbyopia-correcting PCIOLs combining RxSight’s post-operative light-adjustable platform with Alcon’s PCIOL optics. RxSight will receive $60M upfront and up to $140M more on milestones; Alcon leads commercialization, RxSight develops/manufactures and earns royalties.

Swiss stocks ended higher on Thursday after a cautious start. The SMI rose 0.93% to close at 13,341.27 (intraday high 13,395.00). Roche gained 4.2% after developing a research-use-only PCR test for the rare Ebola Bundibugyo virus. Partners Group rose 3.73%; Novartis, Alcon, Sonova and SGS gained 1.6%-2%. Switzerland’s unemployment rate held at 3% in May, SECO said.

Swiss shares ended flat on Tuesday as gains faded while investors weighed differing accounts of Middle East talks between U.S. President Donald Trump and Israeli PM Benjamin Netanyahu. The SMI finished at 13,305.72 versus 13,305.40. VAT Group (+5%), Logitech (+3.7%) and ABB (+3.21%) rose; Roche and Swiss Re fell 1.4%-2.5%. Switzerland’s trade surplus widened to CHF 3.2bn in April.

Algoma Central (TSE:ALC) shares rose above their 50-day moving average on Thursday, trading up to C$22.36 and last at C$22.05 versus a 50-day average near C$21.66–C$21.68. The company reported Q1 EPS of C$0.05 on May 7 on revenue of C$127.78M. It also declared a C$0.21 quarterly dividend (ex-date May 15; pay June 1).

Swiss stocks fell on Thursday as investors stayed cautious amid Middle East tension worries. The SMI ended down 122.65 points (0.9%) at 13,504.76 after opening weak and trading in negative territory. Losers included Partners Group, Swiss Life, Julius Baer, Zurich and Sonova (-2% to -2.5%). Kuehne+Nagel and Lonza rose (+1% to +1.5%). Switzerland non-farm payrolls rose 0.5% y/y to 5.537 million in Q1 2026, per the Federal Statistical Office.